Janssen has submitted two Marketing Authorisation Applications to the EMA for an investigational Ebola vaccine regimen.
List view / Grid view
Filter the results
500,000 regimens of Janssen's investigational Ebola vaccine are to be donated to support the Ebola outbreak response in the Democratic Republic of the Congo.
A Biologics License Application and priority review has been approved by the FDA for an investigational Ebola vaccine.
An Ebola clinical trial has been stopped early as Regeneron's REGN-EB3 therapy shows superiority to ZMapp in preventing Ebola deaths.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
The health minister for the Democratic Republic of the Congo has stated an experimental Ebola vaccine will not be trialled in the country.
A recent report has presented an argument for updating vaccine development during health emergencies to increase efficiency.
The new hub is designed to speed the response to deadly pandemics by improving the development and manufacturing of vaccines – particularly in low- and middle-income countries...